ストックスクリーナーアプリを入手
99.17
0.31%
-0.31
アフターアワーズ：
99.00
-0.17
-0.17%
Merck Co Inc (MRK) 最新ニュース
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal - Benzinga
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Is Merck & Co., Inc. (MRK) Among the Best Low Volatility Stocks to Buy Right Now? - Insider Monkey
Merck wins UK approval for lung disease drug acquired in $11 billion deal - Reuters
2 High-Yield Dividend Stocks to Buy Early in 2025 - The Motley Fool
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79% - Yahoo Finance
Oncology Pharmaceuticals Market Research 2024-2029, - GlobeNewswire
Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024? - Yahoo Finance
Merck & Co. Inc. stock outperforms competitors despite losses on the day - MarketWatch
Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now - Insider Monkey
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Merck & Co. Inc. stock rises Tuesday, still underperforms market - MarketWatch
Merck strikes a $2B GLP-1 deal with Hansoh - BioWorld Online
Wildlife Health Market May See a Big Move | Merck, C.H. Boehringer Sohn - openPR
Merck to discontinue drug for bacterial infection - Reuters
Merck: A Low-Hanging Fruit To Pick (NYSE:MRK) - Seeking Alpha
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and MoreEli Lilly (NYSE:LLY) - Benzinga
Merck - Contract Pharma
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows - AOL
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.8%Time to Sell? - MarketBeat
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus.com
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - MSN
Merck: LM-299 antibody agreement finalized - Marketscreener.com
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - Investing.com
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Rating Lowered to "Market Perform" at BMO Capital Markets - MarketBeat
Merck’s doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials - World Pharmaceutical Frontiers
Merck secures global rights to novel cancer therapy - Investing.com
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Merck & Co buoyed by Phase III results with HIV tablet - The Pharma Letter
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet - Simply Wall St
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla... - Marketscreener.com
Merck stock downgraded by BMO amid Gardasil, Keytruda concerns - Investing.com
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued? - The Acquirer's Multiple
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5%What's Next? - MarketBeat
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga
Merck & Co (MRK) technical analysisMerck & Co (NYSE:MRK), Hansoh Pharmaceutical Gr (OTC:HNSPF) - Benzinga
Merck: encouraging phase III results in HIV - Marketscreener.com
Merck's HIV treatment meets main goal in two late-stage studies - Reuters
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Yahoo Finance
Merck shares reaffirm Market Perform rating on global in-licensing - Investing.com
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug - Yahoo Finance
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market - PharmaVoice
Merck's HIV-1 treatment meets efficacy in Phase 3 trials - Investing.com
Merck's HIV treatment meets main goal of two late-stage studies - Marketscreener.com
Merck stock slips after trial data for HIV drug (MRK:NYSE) - Seeking Alpha
Merck gets rights to Hansoh Pharma’s investigational diabetes drug - World Pharmaceutical Frontiers
Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir - StreetInsider.com
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
0.17%
0.98%
大文字化:
|
ボリューム (24 時間):